Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Shares of NASDAQ TRVN opened at $2.02 on Monday. Trevena has a 52-week low of $1.13 and a 52-week high of $19.23. The firm has a 50 day moving average price of $3.24 and a two-hundred day moving average price of $5.81. The stock has a market cap of $1.74 million, a P/E ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The business had revenue of $0.28 million for the quarter. Analysts predict that Trevena will post -32.25 earnings per share for the current fiscal year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.